Kala Pharmaceuticals Competitors, Revenue and Alternatives
Estimated Revenue & Financials
- Kala Pharmaceuticals's estimated annual revenue is currently $10.7M per year.
- Kala Pharmaceuticals received $110.0M in venture funding in October 2018.
- Kala Pharmaceuticals's estimated revenue per employee is $70,086
- Kala Pharmaceuticals's total funding is $121.2M.
- Kala Pharmaceuticals has 152 Employees.
- Kala Pharmaceuticals grew their employee count by 1% last year.
- Kala Pharmaceuticals currently has 45 job openings.
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding|
|Vita Data Scien...||$10.3M||51||50%||N/A|
What Is Kala Pharmaceuticals?
Kala Pharmaceuticals, Inc. (Kala) is a biopharmaceutical company focused on the development and commercialization of therapeutics using our proprietary nanoparticle-based Mucus Penetrating Particles, or MPP, technology, with an initial focus on the treatment of eye diseases. For more information, please visit Kala's website at www.kalarx.com.keywords:Biotechnology,Cleantech,Healthcare,Pharmaceuticals,Security,Wind Power
Number of Employees
Employee Growth %
|Hongming Chen||Chief Scientific Officer||Email Available|
|Kim Brazzell||Chief Medical Officer|
|Evan Rosenberg||Accounting Manager||Email Available|
|Todd Bazemore||Chief Operating Officer|
|Mary Reumuth||Chief Financial Officer|
|Christine Fiumara||Territory Sales Manager||Email Available|
|Seamus Gillespie||Director Of Finance||Email Available|
|Brett Obrovac||Territory Sales Manager||Email Available|
|Lindy Bolling||Territory Sales Manager - Michigan||Email Available|
|Briana Foster||Director, Commercial Learning & Development||Email Available|
Kala Pharmaceuticals News
Kala Pharmaceuticals, Inc. (KALA), today announced that the Company granted non-statutory stock options to new employees as inducement ...
Kala Pharmaceuticals, Inc. (KALA), a biopharmaceutical company focused on the development and commercialization of therapeutics using its ...
Kala Pharmaceuticals, Inc. (NASDAQ:KALA) is among the top stocks that may remain in focus today as the company shares are trading 3.46% ...
Kala Pharmaceuticals Funding
|2012-03-15||$6.2M||Undisclosed||Lux Capital, Polaris Venture Partners||Article|
|2013-03-01||$11.5M||A||Crown Venture Fund LLC||Article|
|2018-10-03||$110.0M||Undisclosed||Athyrium Capital Management||Article|
Kala Pharmaceuticals Executive Hires
|2013-03-01||Kim Brazzell||Chief Medical Officer||Article|
|2013-05-29||Charles McDermott||EVP Business Development||Article|
|2014-01-07||Howard B. Rosen||Chairman||Article|
|2015-05-15||Mark Iwicki||Executive Chairman||Article|
|2017-11-14||Todd Bazemore||Chief Operating Officer||Article|
|2018-04-04||Eric Trachtenberg||General Counsel and Corporate Secretary.||Article|
|2018-10-26||Steven Zhang||Vice President of Medical Affairs||Article|